In conclusion, BRAF-mutant thyroid cancer cells with constitutive activation of YAP transcriptional activity have intrinsic resistance to RAF kinase inhibitors, driven in part by increased expression of the upstream components of the NRG1 signaling pathway. The gene discussed is YAP1; the disease is thyroid gland carcinoma.